晶泰科技与东阿ST签署免疫学与炎症治疗联合研发谅解备忘录-动脉网

XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies

CISION 等信源发布 2025-08-20 08:00



可切换为仅中文







CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

Aug. 19, 2025

2025年8月19日

/PRNewswire/ -- XtalPi announced on the 20

/PRNewswire/ -- 晶泰科技于20日宣布

that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases.

与韩国领先的制药公司东亚ST签署了一份谅解备忘录（MOU），共同开发免疫和炎症疾病的治疗药物。

This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using XtalPi's proprietary AI-driven drug discovery platform.

此次合作将基于晶泰科技的智能化、自动化药物发现平台，该平台整合了人工智能 (AI)、量子物理和大规模自动机器人实验。两家公司计划利用晶泰科技自主研发的 AI 驱动药物发现平台，共同确定靶点并发现首创或最佳同类药物候选物。

The XtalPi platform combines the speed and generative power of AI with the accuracy of its robotic lab-in-the-loop to accelerate drug discovery and vastly expand the explorable chemical space. This integrated workflow spans deep-learning-based molecule design, quantum physics and molecular dynamics simulations for predicting drug-target interactions, automated chemical synthesis, and experimental validation of candidate compounds' key pharmaceutical properties..

晶泰科技平台结合了人工智能的速度和生成能力，以及其环路机器人实验室的精确性，以加速药物发现并大幅扩展可探索的化学空间。这一集成工作流程涵盖了基于深度学习的分子设计、用于预测药物-靶点相互作用的量子物理和分子动力学模拟、自动化学合成以及候选化合物关键药物特性的实验验证。

Leveraging its expertise in immunology and inflammation as well as its experience in small molecule drug development, Dong-A ST will actively participate throughout the entire R&D process—including candidate validation, efficacy and safety testing, and the formulation of preclinical and clinical development strategies.

利用其在免疫学和炎症方面的专业知识以及在小分子药物开发方面的经验，东亚ST将积极参与整个研发过程，包括候选药物验证、疗效和安全性测试以及临床前和临床开发策略的制定。

The company also plans to explore strategies for pipeline expansion and assess commercialization potential..

公司还计划探索管道扩展的战略，并评估商业化潜力。

Through this partnership, Dong-A ST aims to strengthen its pipeline in the immunology and inflammation space and expand its R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies.

通过此次合作，东亚ST旨在加强其在免疫学和炎症领域的研发管线，并将其研发范围从小分子治疗药物扩展到靶向蛋白降解（TPD）、生物制品、抗体药物偶联物（ADC）和基因治疗等领域。

John Wang

王约翰

, Senior Vice President of Drug Discovery at XtalPi, stated: 'The combination of Dong-A ST's extensive expertise and XtalPi's proven AI-robotics platform is well-positioned to translate scientific innovation into competitive precision medicines. Together, we aim to rapidly discover and rigorously validate novel drug candidates across multiple modalities to unlock unique market opportunities, and deliver transformative therapies for global patients.'.

晶泰科技药物发现高级副总裁表示：“东亚制药的广泛专业知识与晶泰科技经过验证的AI机器人平台相结合，有望将科学创新转化为具有竞争力的精准药物。我们共同的目标是快速发现并严格验证多种模式下的新型候选药物，挖掘独特的市场机会，并为全球患者提供变革性的治疗方案。”

Jae-Hong Park

朴宰弘

, Head of R&D at Dong-A ST, remarked, 'This collaboration marks a pivotal step in expanding Dong-A ST's R&D capabilities,' adding, 'By leveraging synergies with XtalPi's AI platform, we expect to accelerate the development of next-generation treatments for immune and inflammatory diseases.'

“此次合作标志着东阿ST公司研发能力扩展的关键一步，”东阿ST研发部门负责人表示，“通过利用晶泰科技（XtalPi）人工智能平台的协同效应，我们预计将加速下一代免疫和炎症疾病治疗药物的开发。”

Meanwhile, both Dong-A ST and XtalPi operate open innovation offices in

同时，东雅ST和晶泰科技都设有开放创新办公室在

Boston

波士顿

，

USA

美国

. This geographic proximity will facilitate closer and more efficient collaboration throughout the drug discovery process.

这种地理上的邻近性将有助于在整个药物发现过程中促进更紧密、更高效的协作。

About Dong-A ST

关于东亚ST

Dong-A ST Co., Ltd. (170900.KO) was established in 1932 and is a leading Korean pharmaceutical company engaged in the development, manufacturing, and commercialization of ethical drugs, biosimilars, medical devices, and diagnostics. Its key products include

东亚ST公司（170900.KO）成立于1932年，是韩国领先的制药公司，致力于伦理药物、生物仿制药、医疗器械和诊断试剂的开发、生产和商业化。其主要产品包括

Stillen

哺乳

(gastritis),

（胃炎），

Zydena

西地那

(erectile dysfunction),

（勃起功能障碍），

Motilitone

动力тоне

(functional dyspepsia), and

（功能性消化不良），以及

Imuldosa

伊穆尔多萨

(ustekinuma biosimilar). Leveraging strong R&D capabilities and a history of innovation, Dong-A ST is expanding its pipeline in immunology, inflammation, neurological disease, metabolic diseases, and oncology, while advancing into new modalities such as biologics, ADCs, TPD, and gene therapies.

（乌司奴单抗生物类似药）。凭借强大的研发能力和创新历史，东雅ST公司正在免疫学、炎症、神经疾病、代谢疾病和肿瘤学领域拓展其研发管线，同时进军生物制品、抗体药物偶联物（ADC）、TPD和基因治疗等新领域。

About XtalPi

关于晶泰科技

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the

晶泰科技控股有限公司（晶泰科技，2228.HK）由三位物理学家于2015年创立，

Massachusetts Institute of Technology

麻省理工学院

(

MIT

麻省理工学院

). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries..

这是一个由量子物理、人工智能和机器人技术驱动的创新研发平台。通过整合第一性原理计算、人工智能算法、高性能云计算以及标准化自动化系统，晶泰科技为制药、材料科学、农业科技、能源、新化学和化妆品等行业的公司提供数字化和智能化的研发解决方案。

SOURCE XtalPi Inc.

来源：晶泰科技

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers